HRP20080077T3 - Substituted n-cyclohexylimidazolinones having an mch-modulatory effect - Google Patents
Substituted n-cyclohexylimidazolinones having an mch-modulatory effectInfo
- Publication number
- HRP20080077T3 HRP20080077T3 HR20080077T HRP20080077T HRP20080077T3 HR P20080077 T3 HRP20080077 T3 HR P20080077T3 HR 20080077 T HR20080077 T HR 20080077T HR P20080077 T HRP20080077 T HR P20080077T HR P20080077 T3 HRP20080077 T3 HR P20080077T3
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- independently
- another
- alkoxy
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910052717 sulfur Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Spoj formule I, u kojoj su oznakeR1 H, (C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C3-C8)-alkenil, (C3-C8)-alkinil, 3 do 10-člani mono, bi- ili spirociklički prsten koji može uključiti 0 do 4 heteroatoma izabranih iz skupine kisika, dušika i sumpora, gdje sustav prstena može dodatno biti supstituiran s F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkil, O-(C1-C8)-alkil, S-(C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C0-C8)-alkilen-aril, okso, CO(R3), CON(R4)(R5), hidroksi, hidroksi-(C1-C4)-alkil, COO(R6), N(R7)CO(C1-C6)-alkil, N(R8)(R9) ili SO2CH3; R3, R4, R5, R6, R7, R8, R9, neovisno jedan od drugog H, (C1-C6)-alkil; K skupina formule -(CR10R11)z-u kojoj jedna ili više -(CR10R11)- skupina može biti zamijenjena s Z, veza, CşC, C=C; Z O, CO, N(R59), S, SO, SO2;R10, R11 neovisno jedan od drugog H, (C1-C8)-alkil, hidroksi-(C1-C4)-alkil, hidroksi,(C1-C4)-alkoksi-(C1-C4)-alkil, gdje R10 i R11 u zskupinama mogu u svakom slučaju imati ista ili različita značenja; z 1, 2, 3, 4, 5, 6; R59 H, (C1-C8)-alkil; E 3-14-člana bivalentna karbo- ili heterociklička prstenasta struktura koja ima 0-4 heteroatoma iz skupine N, O i S, koji po izboru mogu imati supstituente iz skupine H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, okso, O-(C1-C6)-alkil, O-(C1-C4)-alkoksi-(C1-C4)-alkil, S-(C1-C6)-alkil, (C1-C6)-alkil, (C2-C6)-alkenil, (C3-C8)cikloalkil, O-(C3-C8)cikloalkil, (C3-C8)cikloalkenil, O-(C3-C8)cikloalkenil, (C2-C6)-alkinil, (C0-C8)-alkilen-aril, O-(C0-C8)-alkilen-aril, S-aril, N(R12)(R13), SO2-CH3, COOH, COO-(C1-C6)-alkil, CON(R14)(R15), N(R16)CO(R17), N(R18)SO2(R19), CO(R20) i biti mono ili biciklički; R12, R13, R14, R15, R16, R18 neovisno jedanod drugog H, (C1-C8)-alkil; ili R12 i R13, R14 i R15 neovisno jedan od drugog, po izboru zajedno s dušikovim atomom za koji su vezani, 5-6-člani prsten koji, osim dušikovog atoma, može također uključiti 0-1 daljnjih heteroatoma iz skupine N-(C1-C6)-alkil, kisik i sumpor; R17, R19, R20 neovisno jedan od drugog H, (C1-C8)-alkil, aril; X veza, skupina formule -(CR21R22)y-, u kojoj jedna ili više -(CR21R22)- skupina može biti zamijenjena s Y; Y O, CO, N(R23), S, SO, SO2;R21, R22 neovisno jedan od drugog H, (C1-C4)-alkil, gdje R21 i R22 u y skupinama mogu u svakom slučaju imati ista ili različita značenja; y 1, 2, 3, 4, 5, 6; R23 H, (C1-C8)-alkil; D, G CH ili N; R2 OH, O-(C1-C6)-alkil, O-(C1-C4)-alkoksi-(C1-C4)-alkil, (C1-C6)-alkil; n 0, 1, 2, 3, 4; Q N(R24)(R25), 3 do 8-člani prsten koji možeuključiti 0 do 3 heteroatoma izabranih iz skupinekisik, dušik i sumpor gdje sustav prstena može dodatno biti zamijenjen s (C0-C4)-alkilen-N(R24)(R25), F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkil, O-(C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C0-C8)-alkilen-aril, okso, CO(R26), CON(R27)(R28), hidroksi, hidroksi-(C1-C4)-alkil, COO(R29), N(R30)CO(C1-C6)-alkil ili SO2CH3;R26, R27, R28, R29, R30 neovisno jedan od drugog H, (C1-C6)-alkil; A skupina formule -(C(R31)(R32))m-, u kojoj 0-2 člana mogu bitizamijenjeni s elementom iz skupine O, S, N(R33), CO, SO2;A compound of formula I, wherein R1 is H, (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C3-C8) -alkenyl, (C3-C8) -alkynyl, 3 to 10 membered mono, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system may be further substituted by F, Cl, Br, CF3, NO2, CN, (C1 -C6) -alkyl, O- (C1-C8) -alkyl, S- (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C0-C8) -alkylene- aryl, oxo, CO (R3), CON (R4) (R5), hydroxy, hydroxy- (C1-C4) -alkyl, COO (R6), N (R7) CO (C1-C6) -alkyl, N ) (R9) or SO2CH3; R3, R4, R5, R6, R7, R8, R9, independently of one another H, (C1-C6) -alkyl; K is a group of formula - (CR10R11) z-wherein one or more - (CR10R11) - groups may be replaced by Z, a bond, CşC, C = C; ZO, CO, N (R59), S, SO, SO2, R10, R11 independently of one another H, (C1-C8) -alkyl, hydroxy- (C1-C4) -alkyl, hydroxy, (C1-C4) - alkoxy- (C1-C4) -alkyl, wherein R10 and R11 in the z groups may in each case have the same or different meanings; z 1, 2, 3, 4, 5, 6; R59 H, (C1-C8) -alkyl; E is a 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group N, O and S, which may optionally have substituents from the group H, F, Cl, Br, I, OH, CF3, NO2 , CN, OCF3, oxo, O- (C1-C6) -alkyl, O- (C1-C4) -alkoxy- (C1-C4) -alkyl, S- (C1-C6) -alkyl, (C1-C6) -alkyl, (C2-C6) -alkenyl, (C3-C8) cycloalkyl, O- (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, O- (C3-C8) cycloalkenyl, (C2-C6) -alkynyl , (C0-C8) -alkylene-aryl, O- (C0-C8) -alkylene-aryl, S-aryl, N (R12) (R13), SO2-CH3, COOH, COO- (C1-C6) -alkyl , CON (R14) (R15), N (R16) CO (R17), N (R18) SO2 (R19), CO (R20) and be mono or bicyclic; R12, R13, R14, R15, R16, R18 independently of one another H, (C1-C8) -alkyl; or R12 and R13, R14 and R15 independently of one another, optionally together with the nitrogen atom to which they are attached, a 5-6 membered ring which, in addition to the nitrogen atom, may also include 0-1 further heteroatoms from the group N- (C1 -C6) -alkyl, oxygen and sulfur; R17, R19, R20 independently of one another H, (C1-C8) -alkyl, aryl; X is a bond, a group of formula - (CR21R22) y-, in which one or more - (CR21R22) - groups may be replaced by Y; Y O, CO, N (R23), S, SO, SO2, R21, R22 independently of one another H, (C1-C4) -alkyl, where R21 and R22 in the y groups may in each case have the same or different meanings; y 1, 2, 3, 4, 5, 6; R23 is H, (C1-C8) -alkyl; D, G CH or N; R2 is OH, O- (C1-C6) -alkyl, O- (C1-C4) -alkoxy- (C1-C4) -alkyl, (C1-C6) -alkyl; n is 0, 1, 2, 3, 4; QN (R24) (R25), a 3 to 8 membered ring which may include 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur where the ring system may be further replaced by (C0-C4) -alkylene-N (R24) (R25) , F, Cl, Br, CF3, NO2, CN, (C1-C6) -alkyl, O- (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C0- C8) -alkylene-aryl, oxo, CO (R26), CON (R27) (R28), hydroxy, hydroxy- (C1-C4) -alkyl, COO (R29), N (R30) CO (C1-C6) - alkyl or SO2CH3; R26, R27, R28, R29, R30 independently of one another H, (C1-C6) -alkyl; A group of the formula - (C (R31) (R32)) m-, in which 0-2 members can be replaced by an element from the group O, S, N (R33), CO, SO2;
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004003811A DE102004003811A1 (en) | 2004-01-25 | 2004-01-25 | Substituted N-cyclohexylimidazolinones, processes for their preparation and their use as medicaments |
| PCT/EP2005/000700 WO2005070898A1 (en) | 2004-01-25 | 2005-01-25 | Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080077T3 true HRP20080077T3 (en) | 2008-03-31 |
Family
ID=34745115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080077T HRP20080077T3 (en) | 2004-01-25 | 2008-02-22 | Substituted n-cyclohexylimidazolinones having an mch-modulatory effect |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1711473B1 (en) |
| JP (1) | JP2007518771A (en) |
| KR (1) | KR20060128955A (en) |
| CN (1) | CN1934090B (en) |
| AR (1) | AR047453A1 (en) |
| AT (1) | ATE383342T1 (en) |
| AU (1) | AU2005206308A1 (en) |
| BR (1) | BRPI0507104A (en) |
| CA (1) | CA2554233A1 (en) |
| CY (1) | CY1107429T1 (en) |
| DE (2) | DE102004003811A1 (en) |
| DK (1) | DK1711473T3 (en) |
| ES (1) | ES2297667T3 (en) |
| HR (1) | HRP20080077T3 (en) |
| IL (1) | IL176917A0 (en) |
| MA (1) | MA28345A1 (en) |
| MY (1) | MY139107A (en) |
| NO (1) | NO20063757L (en) |
| PE (1) | PE20051091A1 (en) |
| PL (1) | PL1711473T3 (en) |
| PT (1) | PT1711473E (en) |
| RS (1) | RS50543B (en) |
| RU (1) | RU2006130626A (en) |
| TW (1) | TW200604182A (en) |
| UY (1) | UY28726A1 (en) |
| WO (1) | WO2005070898A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008129679A (en) | 2005-12-21 | 2010-01-27 | Янссен Фармацевтика Н.В. (Be) | NEW SUBSTITUTED PYRAZINONIC DERIVATIVES FOR USE IN SIT-1-MEDIATED DISEASES |
| RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
| AU2007328979B2 (en) | 2006-12-05 | 2013-05-09 | Janssen Pharmaceutica N.V. | Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases |
| KR100893394B1 (en) * | 2007-05-11 | 2009-04-17 | 한국화학연구원 | Imidazole derivatives having aryl piperidine substituents, method for the preparation thereof, and pharmaceutical compositions containing them |
| UY31968A (en) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | NEW HETEROCYCLIC DERIVATIVES, THEIR PROCESSES FOR THEIR PREPARATION, AND THEIR THERAPEUTIC USES |
| DE102008060967A1 (en) * | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylsulfonyltriazolones and their use |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| PL223830B1 (en) | 2012-04-03 | 2016-11-30 | Univ Jagielloński | Derivatives of aromatic imidazolidinones and their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2312637T3 (en) * | 2001-12-04 | 2009-03-01 | Schering Corporation | DERIVATIVES OF N-ARIL-N`-ARILCICLOALQUIL-UREA AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY. |
| DE10233817A1 (en) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
-
2004
- 2004-01-25 DE DE102004003811A patent/DE102004003811A1/en not_active Withdrawn
-
2005
- 2005-01-24 AR ARP050100240A patent/AR047453A1/en not_active Application Discontinuation
- 2005-01-25 JP JP2006550073A patent/JP2007518771A/en not_active Abandoned
- 2005-01-25 PE PE2005000095A patent/PE20051091A1/en not_active Application Discontinuation
- 2005-01-25 CN CN2005800091349A patent/CN1934090B/en not_active Expired - Fee Related
- 2005-01-25 AU AU2005206308A patent/AU2005206308A1/en not_active Abandoned
- 2005-01-25 BR BRPI0507104-6A patent/BRPI0507104A/en not_active IP Right Cessation
- 2005-01-25 RU RU2006130626/04A patent/RU2006130626A/en not_active Application Discontinuation
- 2005-01-25 ES ES05707002T patent/ES2297667T3/en active Active
- 2005-01-25 MY MYPI20050274A patent/MY139107A/en unknown
- 2005-01-25 PL PL05707002T patent/PL1711473T3/en unknown
- 2005-01-25 RS RSP-2008/0082A patent/RS50543B/en unknown
- 2005-01-25 CA CA002554233A patent/CA2554233A1/en not_active Abandoned
- 2005-01-25 KR KR1020067015035A patent/KR20060128955A/en not_active Application Discontinuation
- 2005-01-25 DK DK05707002T patent/DK1711473T3/en active
- 2005-01-25 WO PCT/EP2005/000700 patent/WO2005070898A1/en active Application Filing
- 2005-01-25 DE DE502005002497T patent/DE502005002497D1/en active Active
- 2005-01-25 UY UY28726A patent/UY28726A1/en unknown
- 2005-01-25 PT PT05707002T patent/PT1711473E/en unknown
- 2005-01-25 AT AT05707002T patent/ATE383342T1/en not_active IP Right Cessation
- 2005-01-25 TW TW094102156A patent/TW200604182A/en unknown
- 2005-01-25 EP EP05707002A patent/EP1711473B1/en active Active
-
2006
- 2006-07-17 IL IL176917A patent/IL176917A0/en not_active IP Right Cessation
- 2006-08-03 MA MA29233A patent/MA28345A1/en unknown
- 2006-08-22 NO NO20063757A patent/NO20063757L/en not_active Application Discontinuation
-
2008
- 2008-02-22 HR HR20080077T patent/HRP20080077T3/en unknown
- 2008-03-21 CY CY20081100322T patent/CY1107429T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY28726A1 (en) | 2005-08-31 |
| ES2297667T3 (en) | 2008-05-01 |
| AR047453A1 (en) | 2006-01-18 |
| TW200604182A (en) | 2006-02-01 |
| AU2005206308A1 (en) | 2005-08-04 |
| DK1711473T3 (en) | 2008-05-26 |
| KR20060128955A (en) | 2006-12-14 |
| RS50543B (en) | 2010-05-07 |
| RU2006130626A (en) | 2008-02-27 |
| PL1711473T3 (en) | 2008-05-30 |
| IL176917A0 (en) | 2006-12-10 |
| DE502005002497D1 (en) | 2008-02-21 |
| WO2005070898A1 (en) | 2005-08-04 |
| CA2554233A1 (en) | 2005-08-04 |
| MA28345A1 (en) | 2006-12-01 |
| JP2007518771A (en) | 2007-07-12 |
| CN1934090A (en) | 2007-03-21 |
| BRPI0507104A (en) | 2007-06-19 |
| DE102004003811A1 (en) | 2005-08-11 |
| EP1711473A1 (en) | 2006-10-18 |
| ATE383342T1 (en) | 2008-01-15 |
| CN1934090B (en) | 2010-04-07 |
| MY139107A (en) | 2009-08-28 |
| NO20063757L (en) | 2006-10-11 |
| EP1711473B1 (en) | 2008-01-09 |
| CY1107429T1 (en) | 2012-12-19 |
| PT1711473E (en) | 2008-03-07 |
| PE20051091A1 (en) | 2006-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080077T3 (en) | Substituted n-cyclohexylimidazolinones having an mch-modulatory effect | |
| HRP20070421T3 (en) | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | |
| NO20091562L (en) | 2-aryl-6-phenylimidazole {1,2-alpha} pyridine derivatives, five positions thereof, and therapeutic use thereof | |
| HRP20050628A2 (en) | Substituted benzoyl derivatives uses as herbicides | |
| RS53682B1 (en) | Pyrazinone derivatives and their use in the treatment of lung diseases | |
| ATE556085T1 (en) | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | |
| AR047974A1 (en) | DERIVATIVES OF ALQUILPIPERAZINA AND ALQUILHOMOPIPERAZINA-CARBOXILATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| RS51743B (en) | Macrocyclic inhibitors of hepatitis c virus | |
| HRP20080603T3 (en) | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | |
| AR040230A1 (en) | INDOL, AZAINDOL, AND RELATED HETEROCICLES OF 4-ALQUENIL PIPERIDINA | |
| HRP20070529T3 (en) | Imidazole derivatives as glutmate receptor antagonists | |
| BRPI0413991A (en) | ppar activating compound and pharmaceutical composition containing the same | |
| RS53499B1 (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| CO5580768A2 (en) | DERIVATIVES OF 4,5-DIARILTIAZOL AS LIGANDOS CB-1 | |
| ATE191481T1 (en) | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | |
| NO20055204L (en) | Derivatives of piperidinyl and pipemzinylalkylcarbamates, processes for their preparation and use of the same in therapy | |
| RS51471B (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
| HRPK20040930B3 (en) | Acyl-4-carboxyphenylurea derivatives, method for production and use thereof | |
| RS52552B (en) | Calcitonin gene related peptide receptor antagonists | |
| RS50606B (en) | Substituted morpholine and tiomorpholine derivatives | |
| AR093403A1 (en) | PIRIDIL COMPOUNDS REPLACED WITH USEFUL RENTALS AS MODULATORS OF THE ANSWERS OF IL-12, IL23 AND / OR INFa | |
| AR066107A1 (en) | DERIVATIVES OF TRIAZOLOPIRIDIN - CARBOXAMIDES AND TRIAZOLOPIRIMIDIN-CARBOXAMIDES, THEIR PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS INHIBITORS OF THE GLICEROL LIPASA ENZYMAMONOACIL AND COMPOSITIONS CONTAINING THEM. | |
| AR046080A1 (en) | REPLACED PYRIDINONES | |
| AR064414A1 (en) | DERIVATIVES OF 1-AZONIABICICLO [2, 2, 2] OCTANO AND 1-AZABICICLO [2, 2, 2] OCT-3-ILO, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, PROCEDURE FOR OBTAINING THE SAME, ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF COPD AND A PHARMACEUTICAL PRODUCT THAT | |
| HUP0303825A2 (en) | 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them |